FBN2 and non-small cell lung carcinoma: Additionally, aberrant methylation of FBN2 has been observed in breast cancer, non-small cell lung cancer, and esophageal squamous cell carcinoma [28–30]; FBN2 methylation might negatively impact STS prognosis as well.